Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Infographic – Biomedical Innovation Gains Continue

Chart: medical innovations

Click on image for full-size view. (CB Insights)

7 Aug. 2021. Two statistical indicators provide more evidence that innovations in health and medicine are continuing their sharp upward climb. The data are displayed in a new report, State Of Healthcare Q2’21 Report: Investment & Sector Trends To Watch, issued by the technology intelligence company CB Insights (registration required).

The report is CB Insights’ quarterly review of venture investments in health care, life science, and associated technology companies, including businesses in advanced fields such as artificial intelligence and genomics/proteomics. The report also discusses underlying trends behind these investments, to show how these transactions don’t take place in a vacuum.

One of the CB Insights charts displays two current indicators of medical innovation, side by side. One indicator is the number of references to “breakthrough device designation” or “breakthrough therapy designation” in news articles between July 2016 and June 2021. Breakthrough devices and therapies are Food and Drug Administration programs that offer faster review and more agency attention to medical device or drug candidates showing exceptional promise or addressing unmet medical needs. In that chart, the data show a long-term upward trend, despite short-terms fluctuations, with a particularly sharp increase since the beginning of 2021.

The second chart shows the number of interventional clinical trials registered with, the U.S. government’s clinical trial registry. Interventional studies test the efficacy or safety of specific treatments in human subjects, often against no treatment or a placebo, to gauge their precise effects. That chart shows a continuous upward annual climb in interventional clinical trials since 2010, with an annualized calculation predicting another gain in 2021.

More from Science & Enterprise:

*     *     *

Comments are closed.